

SEQUENCE LISTING

<110> AGENT/REPRESENTATIVE: Greenlee, Winner and Sullivan, P.C.
 APPLICANT: Emory University
 CHAIKOF, Elliot L.
 CAZALIS, Chrystelle S.
 HALLER, Carolyn A.

<120> Thrombomodulin Conjugates

<130> 11-04 WO

<140> PCT/US TO BE ASSIGNED
 <141> 2005-02-22

<150> US 60/546,436
 <151> 2004-02-20

<160> 6

<170> PatentIn version 3.3

<210> 1
 <211> 459
 <212> DNA
 <213> Artificial

<220>
 <223> Synthetic construct

<220>
 <221> CDS
 <222> (8)..(451)

| | |
|---|-----|
| <400> 1 | 49 |
| ggatccc gac ccg tgc ttc aga gcc aac tgc gag tac cag tgc cag ccc | |
| Asp Pro Cys Phe Arg Ala Asn Cys Glu Tyr Gln Cys Gln Pro | |
| 1 5 10 | |
| ctg aac caa act agc tac ctc tgc gtc tgc gcc gag ggc ttc gcg ccc | 97 |
| Leu Asn Gln Thr Ser Tyr Leu Cys Val Cys Ala Glu Gly Phe Ala Pro | |
| 15 20 25 30 | |
| att ccc cac gag ccg cac agg tgc cag ctg ttt tgc aac cag act gcc | 145 |
| Ile Pro His Glu Pro His Arg Cys Gln Leu Phe Cys Asn Gln Thr Ala | |
| 35 40 45 | |
| tgt cca gcc gac tgc gac ccc aac acc cag gct agc tgt gag tgc cct | 193 |
| Cys Pro Ala Asp Cys Asp Pro Asn Thr Gln Ala Ser Cys Glu Cys Pro | |
| 50 55 60 | |
| gaa ggc tac atc ctg gac gac ggt ttc atc tgc acg gac atc gac gag | 241 |
| Glu Gly Tyr Ile Leu Asp Asp Gly Phe Ile Cys Thr Asp Ile Asp Glu | |
| 65 70 75 | |
| tgc gaa aac ggc ggc ttc tgc tcc ggg gtg tgc cac aac ctc ccc ggt | 289 |
| Cys Glu Asn Gly Gly Phe Cys Ser Gly Val Cys His Asn Leu Pro Gly | |
| 80 85 90 | |
| acc ttc gag tgc atc tgc ggg ccc gac tcg gcc ctt gcc cgc cac att | 337 |
| Thr Phe Glu Cys Ile Cys Gly Pro Asp Ser Ala Leu Ala Arg His Ile | |
| 95 100 105 110 | |
| ggc acc gac tgt gac tcc ggc aag gtg gac ggt ggc gac agc ggc tct | 385 |
| Gly Thr Asp Cys Asp Ser Gly Lys Val Asp Gly Gly Asp Ser Gly Ser | |
| 115 120 125 | |
| ggc gag ccc ccg ccc agc ccg acg ccc ggc tcc acc ttg act cct ccg | 433 |

Gly Glu Pro Pro Pro Ser Pro Thr Pro Gly Ser Thr Leu Thr Pro Pro
130 135 140
gcc gtc ggg ggt atg taa tcggatcc 459
Ala Val Gly Gly Met
145

<210> 2
<211> 147
<212> PRT
<213> Artificial

<220>
<223> Synthetic Construct

<400> 2

Asp Pro Cys Phe Arg Ala Asn Cys Glu Tyr Gln Cys Gln Pro Leu Asn
1 5 10 15

Gln Thr Ser Tyr Leu Cys Val Cys Ala Glu Gly Phe Ala Pro Ile Pro
20 25 30

His Glu Pro His Arg Cys Gln Leu Phe Cys Asn Gln Thr Ala Cys Pro
35 40 45

Ala Asp Cys Asp Pro Asn Thr Gln Ala Ser Cys Glu Cys Pro Glu Gly
50 55 60

Tyr Ile Leu Asp Asp Gly Phe Ile Cys Thr Asp Ile Asp Glu Cys Glu
65 70 75 80

Asn Gly Gly Phe Cys Ser Gly Val Cys His Asn Leu Pro Gly Thr Phe
85 90 95

Glu Cys Ile Cys Gly Pro Asp Ser Ala Leu Ala Arg His Ile Gly Thr
100 105 110

Asp Cys Asp Ser Gly Lys Val Asp Gly Gly Asp Ser Gly Ser Gly Glu
115 120 125

Pro Pro Pro Ser Pro Thr Pro Gly Ser Thr Leu Thr Pro Pro Ala Val
130 135 140

Gly Gly Met
145

<210> 3
<211> 147
<212> PRT
<213> Artificial

<220>
<223> Synthetic construct

<220>
<221> MISC_FEATURE

<222> (40)..(40)

<223> Met-388-Leu substitution; position 40

<400> 3

Asp Pro Cys Phe Arg Ala Asn Cys Glu Tyr Gln Cys Gln Pro Leu Asn
1 5 10 15

Gln Thr Ser Tyr Leu Cys Val Cys Ala Glu Gly Phe Ala Pro Ile Pro
20 25 30

His Glu Pro His Arg Cys Gln Leu Phe Cys Asn Gln Thr Ala Cys Pro
35 40 45

Ala Asp Cys Asp Pro Asn Thr Gln Ala Ser Cys Glu Cys Pro Glu Gly
50 55 60

Tyr Ile Leu Asp Asp Gly Phe Ile Cys Thr Asp Ile Asp Glu Cys Glu
65 70 75 80

Asn Gly Gly Phe Cys Ser Gly Val Cys His Asn Leu Pro Gly Thr Phe
85 90 95

Glu Cys Ile Cys Gly Pro Asp Ser Ala Leu Ala Arg His Ile Gly Thr
100 105 110

Asp Cys Asp Ser Gly Lys Val Asp Gly Gly Asp Ser Gly Ser Gly Glu
115 120 125

Pro Pro Pro Ser Pro Thr Pro Gly Ser Thr Leu Thr Pro Pro Ala Val
130 135 140

Gly Gly Met
145

<210> 4

<211> 575

<212> PRT

<213> Homo sapiens

<400> 4

Met Leu Gly Val Leu Val Leu Gly Ala Leu Ala Leu Ala Gly Leu Gly
1 5 10 15

Phe Pro Ala Pro Ala Glu Pro Gln Pro Gly Gly Ser Gln Cys Val Glu
20 25 30

His Asp Cys Phe Ala Leu Tyr Pro Gly Pro Ala Thr Phe Leu Asn Ala
35 40 45

Ser Gln Ile Cys Asp Gly Leu Arg Gly His Leu Met Thr Val Arg Ser
50 55 60

Ser Val Ala Ala Asp Val Ile Ser Leu Leu Leu Asn Gly Asp Gly Gly
Page 3

65

70

75

80

val Gly Arg Arg Arg Leu Trp Ile Gly Leu Gln Leu Pro Pro Gly Cys
85 90 95

Gly Asp Pro Lys Arg Leu Gly Pro Leu Arg Gly Phe Gln Trp Val Thr
100 105 110

Gly Asp Asn Asn Thr Ser Tyr Ser Arg Trp Ala Arg Leu Asp Leu Asn
115 120 125

Gly Ala Pro Leu Cys Gly Pro Leu Cys Val Ala Val Ser Ala Ala Glu
130 135 140

Ala Thr Val Pro Ser Glu Pro Ile Trp Glu Glu Gln Gln Cys Glu Val
145 150 155 160

Lys Ala Asp Gly Phe Leu Cys Glu Phe His Phe Pro Ala Thr Cys Arg
165 170 175

Pro Leu Ala Val Glu Pro Gly Ala Ala Ala Ala Val Ser Ile Thr
180 185 190

Tyr Gly Thr Pro Phe Ala Ala Arg Gly Ala Asp Phe Gln Ala Leu Pro
195 200 205

val Gly Ser Ser Ala Ala Val Ala Pro Leu Gly Leu Gln Leu Met Cys
210 215 220

Thr Ala Pro Pro Gly Ala Val Gln Gly His Trp Ala Arg Glu Ala Pro
225 230 235 240

Gly Ala Trp Asp Cys Ser Val Glu Asn Gly Gly Cys Glu His Ala Cys
245 250 255

Asn Ala Ile Pro Gly Ala Pro Arg Cys Gln Cys Pro Ala Gly Ala Ala
260 265 270

Leu Gln Ala Asp Gly Arg Ser Cys Thr Ala Ser Ala Thr Gln Ser Cys
275 280 285

Asn Asp Leu Cys Glu His Phe Cys Val Pro Asn Pro Asp Gln Pro Gly
290 295 300

Ser Tyr Ser Cys Met Cys Glu Thr Gly Tyr Arg Leu Ala Ala Asp Gln
305 310 315 320

His Arg Cys Glu Asp Val Asp Asp Cys Ile Leu Glu Pro Ser Pro Cys
325 330 335

Pro Gln Arg Cys Val Asn Thr Gln Gly Gly Phe Glu Cys His Cys Tyr
340 345 350

Pro Asn Tyr Asp Leu Val Asp Gly Glu Cys Val Glu Pro Val Asp Pro
 355 360 365

 Cys Phe Arg Ala Asn Cys Glu Tyr Gln Cys Gln Pro Leu Asn Gln Thr
 370 375 380

 Ser Tyr Leu Cys Val Cys Ala Glu Gly Phe Ala Pro Ile Pro His Glu
 385 390 395 400

 Pro His Arg Cys Gln Met Phe Cys Asn Gln Thr Ala Cys Pro Ala Asp
 405 410 415

 Cys Asp Pro Asn Thr Gln Ala Ser Cys Glu Cys Pro Glu Gly Tyr Ile
 420 425 430

 Leu Asp Asp Gly Phe Ile Cys Thr Asp Ile Asp Glu Cys Glu Asn Gly
 435 440 445

 Gly Phe Cys Ser Gly Val Cys His Asn Leu Pro Gly Thr Phe Glu Cys
 450 455 460

 Ile Cys Gly Pro Asp Ser Ala Leu Ala Arg His Ile Gly Thr Asp Cys
 465 470 475 480

 Asp Ser Gly Lys Val Asp Gly Gly Asp Ser Gly Ser Gly Glu Pro Pro
 485 490 495

 Pro Ser Pro Thr Pro Gly Ser Thr Leu Thr Pro Pro Ala Val Gly Leu
 500 505 510

 Val His Ser Gly Leu Leu Ile Gly Ile Ser Ile Ala Ser Leu Cys Leu
 515 520 525

 Val Val Ala Leu Leu Ala Leu Leu Cys His Leu Arg Lys Lys Gln Gly
 530 535 540 545

 Ala Ala Arg Ala Lys Met Glu Tyr Lys Cys Ala Ala Pro Ser Lys Glu
 550 555 560

 Val Val Leu Gln His Val Arg Thr Glu Arg Thr Pro Gln Arg Leu
 565 570 575

<210> 5
 <211> 21
 <212> DNA
 <213> Artificial

 <220>
 <223> Synthetic construct

 <400> 5
 tacccttaact acgacacctgggt g

<210> 6
<211> 18
<212> DNA
<213> Artificial

<220>
<223> Synthetic construct

<400> 6
tatgagcaag cccgaatg

18

Operating System: WinXP Pro, Patentin 3.3
Applicant: Emory University
Title: Thrombomodulin Derivatives and Conjugates
Date data recorded-CFR: February 22, 2005
Atty Docket: 11-01 WO
Int'l Application No.: Not yet assigned
Int'l Filing Date: February 22, 2005
Diskette No.: 1 of 1
Copy to: USPTO/USRO Atty
GREENLEE, WINNER and SULLIVAN, P.C.
4875 PEARL EAST CIRCLE, STE 200
BOULDER, CO 80301
(303) 499-8080
Fax (303) 499-8089

PLEASE ACKNOWLEDGE RECEIPT OF THE FOLLOWING:

1. Certificate of Mailing by Express Mail - 1 page
2. PCT International Application Transmittal Letter - 1 page
3. PCT Request in paper form - 5 pages
4. Fee Calculation page in paper form - 1 page
5. Specification excluding sequence listing (description - 27 pages; claims - 5 pages; abstract - 1 page) - 33 pages
6. 4 sheets of drawings
7. Sequence listing; paper - 6 pages
8. Sequence listing; Computer Readable Form/CRF - 1 diskette
9. Statement under 37 CFR 1.821-824 - 1 page
10. PCT-Safe file on diskette (11-04WO.zip; 11-04WO.log)
11. Check in the amount of \$2,589.00

Attorney Docket No. 11-04 WO
SJP/can: 2/22/05
Express Mail Receipt No.: EV 663 225 151 US

DT07 Rec'd PCT/PTO 22 FEB 2005

PCT/US 05 / 05554

ENT'D MAR 10 2005 EV663225151US